Investing in Innovation. John Bishop CEO & Chairman Baird Healthcare Conference 4 September, 2014
|
|
- Cynthia Webb
- 6 years ago
- Views:
Transcription
1 Investing in Innovation John Bishop CEO & Chairman Baird Healthcare Conference 4 September, Cepheid Cepheid
2 Forward-Looking Statement During the course of this presentation, we may make projections or other forward-looking statements regarding future events or the future financial performance of Cepheid. We wish to caution you that such statements are just projections and that actual events or results may differ materially. We refer you to the documents that we have filed from time to time with the SEC, specifically our last filed Forms 10-K and 10-Q. These documents contain and identify important factors that could cause the actual results to differ materially from those contained in these projections and forward looking statements. 2 Cepheid
3 CPHD: a High Growth Leader in Molecular Diagnostics High Growth Razor/Razor Blade Model Clinical Reagent Sales Grew 25% in 2013 Total Revenue Grew 21% in 2013 Large Installed Base of 7,096 Systems Record 1,084 Systems in Q214 49% CAGR ( ) * Commercial Installed Base: 3,876 HBDC Installed Base: 3,220 Broad and Growing Test Menu 19 Tests Available Today ex-us, 14 in US Extending into High Value/Volume Markets Democratizing Molecular Diagnostics Total Clinical Sales in $ Millions * 2014 Reflects Mid-point of Guidance dated 7/17/14 3 Cepheid
4 Q2 2014: Solid Execution Record 1,084 GeneXpert System Placements More Systems Placed in Second Quarter of 2014 Than All of 2012 Clinical Revenue +27% Total Revenue +21% Continued Menu Execution Xpert HPV CE-IVD in April Xpert Norovirus CE-IVD in April Xpert Carba-R CE-IVD in June 4 Cepheid
5 Continued Investment Supports 3-Pronged Strategy GLOBAL MARKET EXPANSION APPLICABLE MARKET EXPANSION MAINTAINING GROWTH LEADERSHIP BROAD MENU EXPANSION 5 Cepheid
6 Applicable Market Expansion: Early Traction Hospitals Independent Labs Alternative Sites POLs Urgent Care Nursing Homes Retail Clinics Cruise Ships Universities Public Health Home POL s Urgent Care Nursing Homes Retail Outlets Cruise Ships Home 6 Cepheid
7 Independent Reference Labs Infinity System + Broad Xpert Test Menu Opening New Possibilities Highest Volume System Available Unmatched Labor Efficiency LEAN 24/7 Operation Broadest Menu & Most Tests on Board Closed National US Reference Lab 10 Infinity Systems (Reagent Rental) in Process of Roll Out Throughout Q3 Expected to Run ~400,000 Xpert GBS Tests Per Year (When Ramped) Potential for Additional Add-On Tests Discussions Continue with Other Major National US Reference Labs 7 Cepheid
8 Dean Street: High Volume at Point of Care Sexual Health Clinic in Central London Expected to Run 50,000+ Xpert CT/NG Tests in 2014 Service Evaluation: Median time from test to informing patient reduced from 8 days to 1 day Median time to treatment for positive patients reduced from 10 days to 2 days The introduction of the GeneXpert within sexual health services has the potential to reduce the prevalence of CT and NG in the community by reducing the duration of infectivity. 8 Cepheid Wingrove I, McOwan A, Nwokolo N, et al. Sex Transm Infect 2014:90:474
9 Industry Leading Throughput & Operating Efficiency 2:1 Advantage 3:1 Advantage 4:1 Advantage 4:1 Advantage 4:1 Advantage Infinity-80 Gen Probe Tigris Gen Probe Panther BD Viper Roche Cobas Taqman 96 Abbott m Cepheid CT/NG Testing Over One 8-Hour shift
10 Aggressive R&D Investment Continues to Drive Broad Menu Expansion GLOBAL MARKET EXPANSION APPLICABLE MARKET EXPANSION MAINTAINING GROWTH LEADERSHIP BROAD MENU EXPANSION 10 Cepheid
11 Executing Well on Test Menu Expansion Eight Xpert Tests Targeted for 2014 Release Five Delivered: Trich & Flu/RSV CE-IVD This Week Xpert Norovirus (US), Flu/RSV (US), and HIV Viral Load (CE-IVD) Expected by End 2014 Flu/RSV Submitted to FDA at end July Virology Tests Progressing Well Targeting HIV Viral Load CE-IVD End 2014 HIV Viral Load Data at AMP in November Targeting HCV Viral Load, HIV Qualitative CE-IVD Late Q1/Early Q Sharpening Focus on Oncology Tests Xpert Bladder Cancer Now Expected Early 2017 (Was Late 2017) in US 11 Cepheid Xpert Breast Stratifier Now Expected 2016 (Was )
12 Strong Progress on High-Multiplexing "Honeycomb" Completed Prototype Honeycomb GeneXpert System Module Runs in Existing GeneXpert Systems Functioning Microwell PCR Reactions Up to 1,000 Targets Qualitative & Multiplexed Quantitative mrna Expression Completed Prototype Honeycomb GX Tube with Microwells Fluidic Feasibility Achieved Targeted for Release to R&D in 2015 First Commercial Product: Xpert Breast Signature in ex-us 12 Cepheid
13 Xpert Breast Cancer Stratifier Determination of ER, PR, HER2, and Ki67 RNA expression in patients diagnosed with Breast Cancer, supporting physician decisions on appropriate treatment (hormonal, anti-her2, and/or chemotherapy). Using 4uM FFPE section, Pathologist performs H&E stain and macrodissects invasive tumor tissue. Add FFPE lysis reagents and heat. Add ethanol and vortex. Add lysate to GX cartridge. Place cartridge in GeneXpert Total time-to-result <2 hours Rapid, accurate, standardized, cost-effective, and easy to perform. 13 Cepheid
14 Preliminary Studies Show Strong Concordance ER Concordance = 96% 14 Cepheid Positive by Expert Pathologist Negative by Expert Pathologist sample ID ER Expert Path call GX result delta Ct 1 Rich Rich Rich Rich Rich Rich Rich Rich Rich Rich Rich Rich Rich Rich Rich Rich Positive Rich Positive Rich Rich Rich Positive Rich Positive Positive Negative Positive Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative -6.5 High GX values GX Values Compared with Expert Pathologist Calls Low GX values Sample ID HER2 FISH Expert Path call GX result delta Ct 1 Amplified Amplified Amplified Amplified Amplified Amplified Amplified Amplified Amplified Amplified Amplified Amplified Amplified Amplified Amplified Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified Not Amplified -4.6 HER2 Concordance = 100% Positive by Expert Pathologist Negative by Expert Pathologist
15 Xpert Bladder Monitor More Accurate Than Market Leader, With Trademark Ease-of-Use An adjunct to cystoscopy for detection of bladder cancer in: 1. Patients with bladder cancer being monitored for recurrence (Monitoring); and 2. Patients with symptomatic hematuria being evaluated for possible bladder cancer (Detection). Interpretation algorithm incorporates RNA measurements of 4 analytes: CRH, IGF2, ANXA10, UPK1B Transfer urine to preservative tube. Load sample into cartridge. Place cartridge in GeneXpert Total time-to-result 90 minutes 15 Cepheid
16 Xpert Bladder Performing Well Against Market Leader Symptomatic Detection Xpert Bladder (n=43) Source: Early Clinical Data 1 UroVysion (n=51) Source: Package Insert 2 Sensitivity High Grade/CIS 3 100% 88% Grade 3 70% Grade 2 Sensitivity Low Grade 82% 48% Overall Sensitivity 93% 69% Monitoring 16 Cepheid Xpert Bladder (n=78) Source: Early Clinical Data UroVysion (n=49) Source: Package Insert 4 Sensitivity High Grade/CIS 96% 94% Grade 3 78% Grade 2 Sensitivity Low Grade 72% 55% Overall Sensitivity 86% 73% 1. These data are preliminary and validation in independent datasets is proceeding. 2. UroVysion Package Insert Table 15, Comparison of UroVysion Sensitivity to Cystoscopy/Histology by Tumor Grade, Symptomatic 3. CIS: Carcinoma In Situ 4. UroVysion Package Insert Table 6, Comparison of UroVysion Sensitivity to Cystoscopy/Histology by Tumor Grade, Monitoring
17 Updated Targeted Test Menu Available Now Tests MRSA Surveillance SA Nasal Complete C. diff & C. diff/epi vana for VRE MRSA/SA SSTI MRSA/SA Blood Culture EV Flu MTB/RIF CT/NG GBS & GBS Lim Broth Factor II&V 19 Tests Norovirus Carba-R MRSA Surveillance-Next Gen Flu/RSV (Submitted) CW Flu/RSV Trichomonas 33 Tests SA Nasal Complete-Next Gen Pertussis GI Panel HSV 1/2 Typing Vaginitis CW Vaginitis CW CT/NG HPV (Cervical CA) HIV Quant HCV Quant HBV Quant BCR-ABL Ultra Breast CA Stratifier Bladder CA Monitor Bladder CA Symptomatic 39 Tests Group A/C Strep Meningitis/Encephalitis GBS Ultra CW GBS Ultra CW Group A/C Strep CW HPV (Cervical CA) Breast CA Signature 19 Tests MRSA Surveillance SA Nasal Complete C. diff/epi vana/vanb for VRE MRSA/SA SSTI MRSA/SA Blood Culture Norovirus (Q214) Carba-R (Q214) EV Flu Flu/RSV (NEW in Q314) MTB/RIF CT & CT/NG Trichomonas (NEW in Q314) GBS HPV (Cervical CA) (Q214) Factor II&V BCR-ABL Monitor 17 Cepheid 24 Tests MRSA Surveillance-Next Gen HIV Quant (2014) HIV Qualitative HCV Quant BCR-ABL Ultra Bladder CA Monitor/Symptom 33 Tests Notes: Targeted Test Menu Subject to Revision; CW = CLIA-Waived Tests in Italics Represent Product Improvements and are Excluded from Total Test Counts SA Nasal Complete-Next Gen Group A/C Strep Meningitis/Encephalitis Pertussis GI Panel HSV 1/2 Typing Vaginitis GBS Ultra HBV Quant Breast CA Stratifier Breast CA Signature 36 Tests Pancreatic CA Monitor EBV / NPC Screen EBV / NPC Monitor = US Tests = International Tests
18 Firm Commitment to Targeted 2017 Business Model No Change to Target Established at 2012 Analyst Event Gross Margin Target* High 60s Research & Development 15-16% Comment GM was 62% in Q214 Highest Volume Tests Already >70% MRSA COGS <$5 (excluding Royalty) Heavy Clinical Trial Expenses (HPV, Virology) Step Down in 2017 Sales & Marketing ~18% General & Administrative ~8% Operating Margin Mid 20s * All targets are Non-GAAP and apply to our Commercial Business only (excluding HBDC) 18 Cepheid
19 We are a better way. 19 Cepheid Cepheid NASDAQ: CPHD Questions? Contact Investor Relations: investor.relations@cepheid.com or tel. (408)
Jefferies Healthcare Conference. John Bishop Chairman & CEO June 2, 2014
Jefferies Healthcare Conference John Bishop Chairman & CEO June 2, 2014 1 Cepheid Cepheid Worldwide Market Growth by Segment Overall IVD sales are projected to grow at a 5.9% CAGR through 2017. Molecular
More informationWe Innovate for Life John Bishop Chairman and Chief Executive Officer June 2016
We Innovate for Life John Bishop Chairman and Chief Executive Officer June 2016 1 Cepheid Forward-Looking Statement During the course of this presentation, we may make projections or other forward-looking
More informationCepheid The MDx Growth Leader. William Blair Growth Stock Conference June 12, 2012
Cepheid The MDx Growth Leader William Blair Growth Stock Conference June 12, 2012 Forward Looking Statement During the course of this presentation, we may make projections or other forward looking statements
More informationCepheid: Delivering a Better Way
Cepheid: Delivering a Better Way Dieneke Brockmans March 14, 2017 1 Cepheid Our Mission Delivering a better way to improve patient outcomes by enabling access to molecular diagnostic testing everywhere.
More informationUnified Xpert MTB/RIF Forecasting Initiative
Photo: Riccardo Venturi Unified Xpert MTB/RIF Forecasting Initiative Wayne van Gemert WHO Global TB Programme, Geneva WHO ANNUAL MEETING WITH HIV DIAGNOSTIC MANUFACTURERS AND STAKEHOLDERS 11 March 2016
More information2017 & Beyond Next Phase Innovative Growth Drivers. Analyst Event July 27, 2015
2017 & Beyond Next Phase Innovative Growth Drivers Analyst Event July 27, 2015 1 Forward-Looking Statement During the course of this presentation, we may make projections or other forward-looking statements
More informationCepheid Update POC QA. Gwynn Stevens, PhD Director Virology Programme HBDC
Cepheid Update POC QA Gwynn Stevens, PhD Director Virology Programme HBDC What will be covered? Quick intro to Cepheid Identification of the need Recognition of the challenges Technology as part of the
More informationGeneXpert System. On-Demand Molecular Testing for the Physician Office Laboratory
On-Demand Molecular Testing for the Physician Office Laboratory GeneXpert System How can on-site testing positively impact patient care and clinic operations? A better way. On-site molecular diagnostics
More informationThe difference in cancer detection
in cancer detection 1 Introduction The difference in cancer detection Cxbladder Cxbladder is a non-invasive laboratory test for the detection of bladder cancer that gives you actionable results, which
More informationDisruptive innovation in molecular diagnostics. Hilde Windels CEO Biocartis 25 March 2017
Disruptive innovation in molecular diagnostics Hilde Windels CEO Biocartis 25 March 2017 1 One of the key innovations in healthcare in the last decade PERSONALISED MEDICINE or HIGH PRECISION MEDICINE From
More informationRoche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationInfectious Disease Diagnostics
Infectious Disease Diagnostics Tackling Infectious Diseases Uppsala Health Summit - October10 th, 2017 Stephan Jäger, Roche Diagnostics GmbH When to tackle infectious diseases Prevention & action contribution
More informationInnovations in nucleic acid amplification technologies. Automated platforms for NAT. Microfluidics Digital PCR Innovations in nucleic acid microarrays
About the author Disclaimer EXECUTIVE SUMMARY Molecular diagnostic technologies Healthcare-associated infections Sexually transmitted HPVs HIV and hepatitis viruses Market outlook and forecasts Molecular
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationEconomic Value Lab Efficiencies Safety Clinical Outcomes. Visit BD Booth AACC/ASCLS 2009 Annual Meeting
Economic Value Lab Efficiencies Safety Clinical Outcomes Visit BD Booth 1225 AACC/ASCLS 2009 Annual Meeting BD Events & Co-Promotions Join us this year at booth #1225 to discover the full spectrum of solutions
More informationOraSure Technologies. JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE June 4, 2014
OraSure Technologies JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE June 4, 2014 Forward-Looking Statements These slides and the associated presentation contain certain forward-looking statements, including
More informationSEXUAL HEALTH LAB PRODUCTS
SEXUAL HEALTH LAB PRODUCTS Quick, reliable results for in-office testing Start treatments sooner. Enhance patient outcomes. Long waits for results. Delayed diagnosis and treatment. Cancelled follow-up
More informationCommercial Assays an Overview. Molecular Workshop
Commercial Assays an Overview Molecular Workshop Commercial Assays By Discipline Infectious Disease Blood borne viruses Respiratory Viruses and Bacteria Enteropathogens STD s bacteria, viruses and parasites,
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationOverview of HIV Testing Practices and Technology
Overview of HIV Testing Practices and Technology 2019 HIV Diagnostics Conference March 25 th, 2019 Michele Owen, Ph.D National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers for Disease
More informationPoint of Care Tests for respiratory viruses: impact on clinical outcomes of patients
Point of Care Tests for respiratory viruses: impact on clinical outcomes of patients Dr Sacha Stelzer-Braid Postdoctoral Scientist Virology Research Laboratory (VRL), UNSW and POWH @DrSachaSB Outline 1.
More informationHIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2018Oct26
1 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Viral Load Quality Assessment Program Summary
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationMyriad Genetics Corporate Presentation 6/4/13
Myriad Genetics Corporate Presentation 6/4/13 Forward Looking Statement Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationAVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect
More informationRoche to provide HIV diagnostic solutions to Global Fund. Framework agreement with Global Fund strengthens access to HIV diagnostics
Media Release June 18, 2015 Roche to provide HIV diagnostic solutions to Global Fund Framework agreement with Global Fund strengthens access to HIV diagnostics Roche (SIX: RO, ROG; OTCQX: RHHBY) announced
More informationDiagnostics: Bench to Bedside Pathway
Diagnostics: Bench to Bedside Pathway Rosanna W Peeling Professor and Chair, Diagnostic Research Director, International Diagnostics Centre London School of Hygiene & Tropical Medicine www.idx-dx.org The
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationPoint-of-Care Molecular Testing
Point-of-Care Molecular Testing Waived Testing April 28, 2016 Raymond P. Podzorski, Ph.D., D(ABMM) Ph.D. Microbiologist St. Mary s Hospital Laboratory Wisconsin Region SSMHC Madison, WI 608-258-6393 raymond_podzorski@ssmhc.com
More informationHEV Assay Development Update
HEV Assay Development Update Jeffrey M. Linnen, Ph.D. Senior Director, Research & Development Hologic Gen-Probe, San Diego, California USA IPFA/PEI 20th International Workshop on Surveillance and Screening
More informationMyriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016
Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other
More informationNon-competitive Internal Control Concept for PCR-based Qualitative Assays
Christian O. Simon Roche Molecular Diagnostics Rotkreuz, CH Non-competitive Internal Control Concept for PCR-based Qualitative Assays 23 rd SoGAT Meeting, 16 th 17 th April, 2012, Vilnius, Lithuania Design
More informationfor Microbiology Quality Assessment Programmes for HPV and MRSA Effect of change to assessment categories for HBV DNA Dr Vivienne James SoGAT 2009
for Microbiology Quality Assessment Programmes for HPV and MRSA Effect of change to assessment categories for HBV DNA Dr Vivienne James Overview Update on the HPV scheme introduced in 2009 MRSA screening
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationNASDAQ: CPHD. Defining on-demand molecular diagnostics
NASDAQ: CPHD Defining on-demand molecular diagnostics Forward Looking Statement During the course of this presentation, we may make projections or other forward looking statements regarding future events
More informationSiemens Healthcare Diagnostics
Siemens Healthcare Diagnostics A Global Industry Leader 3.7bn in sales More than 14,500 employees Serving 30,000 customers in more than 120 countries Approximately 244,000 instruments installed R&D spending
More informationPersonalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc
1 Personalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc Safe Harbor Statement This presentation contains forward-looking statements within the meaning
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationThe Clinical Need for Antibiotic Resistance Related Diagnostics Professor Mark H. Wilcox
The Clinical Need for Antibiotic Resistance Related Diagnostics Professor Mark H. Wilcox Leeds Teaching Hospitals, University of Leeds, & Public Health England, UK Facts (i) IVDs will be the world s largest
More informationTrends in molecular diagnostics
Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling
More informationXpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it
Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it Angela Starks, PhD Chief, Laboratory Branch Division of TB Elimination Matt Bankowski, PhD, MS, D(ABMM), HCLD/CC(ABB)
More informationSchedule of Accreditation
Schedule of Accreditation Organisation Name National Virus Reference Laboratory INAB Reg No 326MT Contact Name Eimear Malone Address University College Dublin, Belfield, Dublin Contact Phone No 01-7161319
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Royal Liverpool & Broadgreen University Hospitals NHS Trust Department of Virology Liverpool Clinical Laboratories Royal Liverpool and Broadgreen
More informationOpportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests
Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests Ann Winters, MD Medical Director, Viral Hepatitis Program, Bureau of Communicable Disease, New York City Department of Health and Mental
More informationOpportunities and Challenges in the Development of Companion Diagnostics
Opportunities and Challenges in the Development of Companion Diagnostics E. Patrick Groody, Ph.D. Divisional Vice President Research and Development Abbott Molecular Agenda Value of Personalized Medicine
More informationDiagnostics HPV Testing
22 SOURCES COMPANIES: HOLX, QGEN, RHHBY, ROG VX BDX HOLX S HPV TESTING BUSINESS QGEN S HPV TESTING BUSINESS Roche Leads in HPV Platform Switches Roche s cobas continues to capture the majority of HPV platform
More informationNew CT/GC Tests. CDC National Infertility Prevention Project Laboratory Update Region II May 13-14, 2009
CDC National Infertility Prevention Project Laboratory Update Region II May 13-14, 2009 Richard Steece, Ph.D., D(ABMM) DrRSteece@aol.com New CT/GC Tests New Nucleic Acid Amplification Tests (NAATs) for
More informationDiagnostics Division. Daniel O Day COO Roche Diagnostics
1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationMolecular Diagnostic Solutions for Urologic Cancer
1 Molecular Diagnostic Solutions for Urologic Cancer 2017 First Half Results Presented on 31 August 2017 Dr. Jan Groen, President & CEO Mr. Jean-Marc Roelandt, EVP & CFO 2 Forward looking statement This
More informationAnti-Infective Clinical Trials
Anti-Infective Clinical Trials The extensive clinical training and experience of our infectious disease staff places us in a unique position to fully appreciate the requirements of our clients conducting
More informationUPDATE MOLECULAR DIAGNOSTICS IN SEXUAL HEALTH. Dr Arlo Upton Clinical Microbiologist Labtests Auckland
UPDATE MOLECULAR DIAGNOSTICS IN SEXUAL HEALTH Dr Arlo Upton Clinical Microbiologist Labtests Auckland Talk outline Chlamydia trachomatis NAAT What does a positive test mean Interpreting low level positives
More informationWalgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs
Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationThe difference in cancer detection
in cancer detection Patient Information Bladder cancer is a type of cancer that begins in your bladder. It often starts in the cells that line the inside of the bladder and can grow into the deeper bladder
More informationMenu and flexibility with the QIAscreen HPV PCR Test
Menu and flexibility with the QIAscreen HPV PCR Test Sample to Insight HPV and Cervical cancer Worldwide, HPV is one of the most common STIs Persistent infection with high-risk HPV types is linked to virtually
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationNew Generation of Nucleic Acid Testing. Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention
New Generation of Nucleic Acid Testing Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention Percentage (%) Persons Living with Diagnosed or Undiagnosed HIV Infection
More informationThe clearest path to the most meaningful results. The cobas HPV Test delivers clinical value with workflow efficiencies every step of the way
The clearest path to the most meaningful results The cobas HPV Test delivers clinical value with workflow efficiencies every step of the way The cobas HPV Test KNOW THE RISK Help guide clinical decision
More informationAMPLIRUN TOTAL A RELIABLE QUALITY CONTROL SOURCE FOR NUCLEIC ACID TESTS
AMPLIRUN TOTAL A RELIABLE QUALITY CONTROL SOURCE FOR NUCLEIC ACID TESTS Take Control, Molecular Control. 02 04 05 06 06 07 08 08 AMPLIRUN TOTAL RESPIRATORY INFECTIONS TUBERCULOSIS INFECTIONS GASTROINTESTINAL
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationPanther has new prey
Raising the Bar for Performance Testing Panther has new prey The Aptima HIV-1 Quant Dx assay leads the hunt for HIV-1 diagnosis and viral load monitoring. Freedom to work the way you choose Run what assays
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationReliable, cost-effective CT/GC testing For labs with low to medium throughput needs. The BD ProbeTec ET System
Reliable, cost-effective CT/GC testing For labs with low to medium throughput needs The BD ProbeTec ET System The demand is there. The system is here. Now your lab can run up to 15,000 samples a year reliably
More informationUroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011
Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationAbout HPV. Human papillomavirus (HPV) is a group of viruses that are extremely common worldwide. Theree are more than 100 types of HPV, of which at
Cervical Cancer & HPV What is HPV Human papillomavirus (HPV) is a group of viruses that are extremely common worldwide. About HPV Theree are more than 100 types of HPV, of which at least 13 are cancer-causing
More information+ use molecular testing to help drive my patients treatment plans.
+ use molecular testing to help drive my patients treatment plans. Xpert Bladder Cancer Detection & Xpert Bladder Cancer Monitor In Vitro Diagnostic Medical Device Not all tests available in all countries.
More informationMedia Contact: Ron Rogers Investor Contact: Scott Gleason (801) (801)
News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Receives FDA Approval of BRACAnalysis CDx as Companion
More informationThe Application of molecular POCT for Influenza and Group A Strep Detection
The Application of molecular POCT for Influenza and Group A Strep Detection Gregory J. Berry, Ph.D., D(ABMM) Assistant Professor, Pathology and Laboratory Medicine Zucker School of Medicine at Hofstra/Northwell
More informationIn Situ Hybridization: Market Strategies and Forecasts, US,
In Situ Hybridization: Market Strategies and Forecasts, US, 2018-2024 Table of Contents In Situ Hybridization: Executive Summary The study is designed to give a comprehensive overview of the In Situ Hybridization
More informationFirst Albany Orthopedics Conference Marina Village, San Diego February 13, 2007 Orthofix International
First Albany Orthopedics Conference Marina Village, San Diego February 13, 2007 Orthofix International Tom Hein, CFO Safe Harbor Statement Except for historical information contained herein, the statements
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationcobas Liat System Lab in a tube
cobas Liat System Lab in a tube Roche Molecular Diagnostics A rich history of innovation in PCR & molecular automation 1983 2009 2014 Discovery of PCR 1988 AMPLICOR MONITOR 1995 1998 LightCycler Instrument
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationVolitionRx Announces First Quarter 2016 Financial Results and Business Update
May 13, 2016 VolitionRx Announces First Quarter 2016 Financial Results and Business Update NAMUR, Belgium, May 13, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused
More information21 st Annual Needham Growth Conference
21 st Annual Needham Growth Conference Title January 15, 2019 Bonnie Anderson Chairman and Chief Executive Officer Forward-Looking Statements This presentation contains forward-looking statements, within
More information8/18/2011. How Far We ve Come. Update on Laboratory Diagnosis of Viral Infections. Rapid Viral Diagnostic Techniques. Goals of Testing for Viruses
How Far We ve Come Update on Laboratory Diagnosis of Viral Infections Jim Dunn, Ph.D., D(ABMM) Cook Children s Medical Center Ft. Worth, TX 1948 cell culture techniques standardized 1956 immunofluorescent
More informationFifteen years of molecular EQA: progress and challenges
Fifteen years of molecular EQA: progress and challenges Anton M van Loon 1, Stuart West 2 and Paul Wallace 2 1 Department of Virology, UMC Utrecht, The Netherlands 2 QCMD, Glasgow, Scotland Key Issues
More informationEvolution of HIV Diagnostics. Goals for the 2010 Conference. Bernard M. Branson, M.D. CDC Division of HIV/AIDS Prevention
Evolution of HIV Diagnostics and Goals for the 2010 Conference Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics CDC Division of HIV/AIDS Prevention Evolution or other influences like
More informationQuotient Limited. 36 th Annual JP Morgan Healthcare Conference. San Francisco, January 2018 THE FUTURE, MADE POSSIBLE
Quotient Limited 36 th Annual JP Morgan Healthcare Conference San Francisco, January 2018 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of
More informationBALCHEM CORPORATION. Q Investor Relations Presentation
BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life
More informationCommunity-Based Point-of-Care Testing: From Innovative Care Model to Common Practice
Community-Based Point-of-Care Testing: From Innovative Care Model to Common Practice Donald G. Klepser, PhD, MBA Associate Professor University of Nebraska Medical Center Brian Bobby Rite Aid Vice President,
More informationPractical Aspects of Standardisation for a Global Controls Manufacturer
Practical Aspects of Standardisation for a Global Controls Manufacturer MRSA SoGAT Clinical Diagnostic Meeting NIBSC, UK June 25, 2008 Frank Opdam PhD, AcroMetrix Standardisation A fundamental goal of
More informationMAGFORCE AG FIGHTING CANCER WITH NANO MEDICINE
MAGFORCE AG FIGHTING CANCER WITH NANO MEDICINE 2014, Berlin, Germany 2 EXECUTIVE SUMMARY Company Profile Headquartered in Berlin, Germany Current Management Team: B. Lipps, H. Tawfik, C. von Volkmann Frankfurt
More informationLiquid Biopsy Applications on the Idylla Fully Integrated Sample-to-Result MDx System
Liquid Biopsy Applications on the Idylla Fully Integrated Sample-to-Result MDx System Erwin Sablon, Head of R&D, Biocartis NV World CDx, Boston, September 10 th 2015 0 About Biocartis Innovative molecular
More informationSimpler QC for your Quality Systems. Thermo Scientific AcroMetrix Molecular Standards and Quality Controls. North American version
Simpler QC for your Quality Systems Thermo Scientific AcroMetrix Molecular Standards and Quality Controls North American version AcroMetrix Contents Introduction 4 Superior QC: AcroMetrix molecular quality
More informationAnalytical and economic evaluation of the fully automated Xpert BCR-ABL assay from Cepheid
Analytical and economic evaluation of the fully automated Xpert BCR-ABL assay from Cepheid Jean-Michel Cayuela Saint-Louis hospital Paris July 5, 2012 Talk outline Chronic myeloid leukemia > Genetic bases,
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies Healthcare Conference June 2015 Disclosure Notice This presentation may contain projections and other forward-looking statements
More information4 th Quarter 2017 Earnings Review & Investor Update
4 th Quarter 2017 Earnings Review & Investor Update February 5, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking
More informationMDxHealth. AssureMDx leaves competition behind. Research Note.
Research Note MDxHealth AssureMDx leaves competition behind Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date:
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK West of Scotland Specialist Virology Centre New Lister Building Level 5 Glasgow Royal Infirmary 10-16 Alexandra Parade Glasgow G31 2ER Contact:
More informationFinancial Presentation
Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with
More informationHIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2017Oct27
1 The National Laboratory for HIV Reference Services is Accredited to ISO 15189 and ISO 17043 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology
More informationCritical Care. Building Future Growth with Innovation. Katie M. Szyman Corporate Vice President, Critical Care
Katie M. Szyman Corporate Vice President, Building Future Growth with Innovation Products Benefit Millions of Patients per Year Our new HemoSphere capital platform strengthens our core portfolio We are
More informationMyriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018
Myriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018 Copyright 2017 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Forward Looking Statements
More informationNon-Invasive Array Based Screening for Cancer. Dr. Amit Kumar President and CEO CombiMatrix Corporation
Non-Invasive Array Based Screening for Cancer Dr. Amit Kumar President and CEO CombiMatrix Corporation www.combimatrix.com May 13, 2009 This presentation contains forward-looking statements within the
More information